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Abstract
Background: The Aptima HCV Quant Dx assay (Aptima assay) is a fully automated quantitative assay on the
Panther® system. This assay is intended for confirmation of diagnosis and monitoring of HCV RNA in plasma and
serum specimens. The purpose of the testing described in this paper was to evaluate the performance of the
Aptima assay.
Methods: The analytical sensitivity, analytical specificity, precision, and linearity of the Aptima assay were assessed.
The performance of the Aptima assay was compared to two commercially available HCV assays; the Abbott
RealTime HCV assay (Abbott assay, Abbott Labs Illinois, USA) and the Roche COBAS Ampliprep/COBAS Taqman HCV
Quantitative Test v2.0 (Roche Assay, Roche Molecular Systems, Pleasanton CA, USA). The 95% Lower Limit of
Detection (LoD) of the assay was determined from dilutions of the 2nd HCV WHO International Standard (NIBSC 96/
798 genotype 1) and HCV positive clinical specimens in HCV negative human plasma and serum. Probit analysis
was performed to generate the 95% predicted detection limits. The Lower Limit of Quantitation (LLoQ) was
established for each genotype by diluting clinical specimens and the 2nd HCV WHO International Standard (NIBSC
96/798 genotype 1) in HCV negative human plasma and serum. Specificity was determined using 200 fresh and 536
frozen HCV RNA negative clinical specimens including 370 plasma specimens and 366 serum specimens. Linearity
for genotypes 1 to 6 was established by diluting armored RNA or HCV positive clinical specimens in HCV negative
serum or plasma from 8.08 log IU/mL to below 1 log IU/mL. Precision was tested using a 10 member panel made
by diluting HCV positive clinical specimens or spiking armored RNA into HCV negative plasma and serum. A
method comparison was conducted against the Abbott assay using 1058 clinical specimens and against the Roche
assay using 608 clinical specimens from HCV infected patients. In addition, agreement between the Roche assay
and the Aptima assay using specimens with low HCV concentrations (</= 25 IU/mL by Roche) was tested using
107 clinical specimens.
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Results: The 95% LoD was 5.1 IU/mL or lower for serum and 4.8 IU/mL or lower for plasma depending on the HCV
genotype. The LLoQ for the assay was 10 IU/mL. Specificity was 100% with 95% confidence intervals of 99.6 to
100% for serum and plasma data combined. The assay demonstrated good linearity across the range for all
genotypes. The Precision as estimated by the standard deviation (sd) was 0.17 log or lower across the range of the
assay for both serum and plasma. HCV viral load results were compared using the Aptima assay and the Abbott
assay giving a slope of 1.06, an intercept of 0.08 and an R2 of 0.98. HCV viral load results were compared for the
Aptima and Roche assays giving a slope of 1.05, an intercept of −0.12 and an R2 of 0.96. Positive and negative
agreement for the Aptima assay vs the Roche assay was 89% for low level specimens.
Conclusion: The Aptima assay is a highly sensitive and specific assay. The assay gave comparable HCV viral load
results when compared to the Abbott and Roche assays. The performance of the Aptima assay makes it an
excellent candidate for the detection and monitoring of HCV.
Background
Hepatitis C virus (HCV) infection remains an important
world-wide health concern with 130 – 150 million
people infected [1]. Approximately 75–85% of HCV-
infected persons will progress to chronic HCV infection
and are at risk for the development cirrhosis, and hepa-
tocellular carcinoma (HCC) [2]. Most people infected
with HCV are asymptomatic but the risk of HCC is sub-
stantially higher in HCV infected patients compared to
HCV negative subjects [3]. The CDC estimates that 1 –
5% of those chronically infected with HCV will die from
end stage liver disease due to either cirrhosis or hepato-
cellular carcinoma [4].
Recently developed direct acting antiviral treatments
for HCV can eliminate the virus from almost all patients
[5]. The elimination of HCV is measured by a sustained
virological response (SVR). SVR is defined as an
undetectable HCV RNA plasma/serum concentration at
12 or 24 weeks after treatment completion using a sensi-
tive HCV RNA quantitation assay with a limit of quanti-
tation of under 25 IU/ml [6]. The risks of HCC and
mortality are reduced in patients achieving SVR
compared to the risks in untreated patients [7].
CDC, AASLD/IDSA and EASL guidelines recommend
the use of quantitative HCV RNA testing for pre-
treatment and on-treatment patient monitoring and
management. Quantitative HCV nucleic acid amplifica-
tion test (NAAT) results prior to initiating HCV therapy
are used to determine the baseline level of viral load,
and these results guide decisions for treatment regimens
and durations [6, 8, 9]. For diagnosing HCV infections,
CDC and AASLD/IDSA recommend initial testing with
an HCV antibody test (anti-HCV test). A positive HCV
antibody test result is indicative of an active HCV infec-
tion or previous HCV infection. An HCV NAAT is rec-
ommended to confirm the presence of an active HCV
infection or reinfection, after previous viral clearance, in
a patient following a positive HCV antibody test result
[6, 8]. In addition, HCV NAAT testing is also recom-
mended for patients with negative antibody results, if
they are immunocompromised or have been exposed to
the Hepatitis C virus within last six months. EASL rec-
ommends the use of a sensitive molecular test for HCV
RNA for the diagnosis of HCV infection [9].
During HCV therapy, HCV quantitative assays are im-
portant tools for determining the effectiveness of HCV
treatment. Guidelines from the AASLD and EASL
suggest testing HCV RNA not only at baseline, but also
periodically during treatment (i.e., 4, 12 weeks) and at
completion of treatment (i.e., 8 or 12 weeks) and post-
treatment (i.e., 12 or 24 weeks); [6, 9, 10].
This paper presents the data from studies using the
Aptima HCV Quant Dx (Aptima; Hologic, Inc., San
Diego, CA, USA) assay. This is a quantitative HCV RNA
assay for monitoring and diagnosing of HCV infection on
the fully automated Panther system. The Aptima assay
uses real-time transcription-mediated amplification
(TMA) to amplify the RNA target (5’-UTR) of HCV geno-
types 1 to 6 [11]. The assay uses a negative and two posi-
tive controls to validate accuracy of the results. The assay
has a dynamic range of 10 to 100,000,000 IU/mL and uses
500uL of serum or plasma in each reaction. Performance
characteristics tested include 95% limit of detection (LoD),
lower limit of quantitation (LLoQ), equal genotype detec-
tion, linearity precision and specificity. The results of clin-
ical specimens tested with the Aptima assay were




The linear range of the Aptima assay was demonstrated
by testing panels of HCV armored RNA or clinical speci-
mens diluted in HCV negative human plasma and
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serum. Panels ranged in concentration from 8.08 log IU/
mL to less than 1 log IU/mL. Armored RNA was used
to make panels above 6 log IU/mL. A combination of
diluted clinical specimens or armored RNA was used to
make lower concentrations panels.
Analytical Sensitivity (Limit of Detection, LoD)
The LoD was determined by testing dilutions of the
WHO 2nd International Standard for Hepatitis C Virus
RNA (NIBSC 96/798, genotype 1) in HCV negative hu-
man plasma and serum. A total of 10 panel members
(0.25, 0.50, 1, 2, 3, 6, 8, 10, 12 and 20 IU/mL) were
tested over 3 days on 3 Panther systems with 3 reagent
lots for a total of 108 replicates per panel member (36
replicates per lot). In addition, The LoD across geno-
types was determined by testing dilutions of HCV posi-
tive clinical specimens for genotypes 1, 2, 3, 4, 5 and 6
in HCV negative human plasma and serum. The HCV
concentration for each clinical specimen was determined
by testing with an FDA approved commercially available
HCV quantitative assay. Each panel was tested on three
Panther systems over 3 days with 3 reagent lots. A mini-
mum total of 60 replicates were tested for each panel
member (minimum 20 replicates per reagent lot). Probit
analysis was performed on the Aptima results using SAS
software to calculate the LoD for 95% detection rates.
Analytical Sensitivity (Lower Limit of Quantitation, LLoQ)
The LLoQ was determined by testing dilutions of the
WHO 2nd International Standard for Hepatitis C Virus
RNA (NIBSC 96/798, genotype 1) in HCV negative
human plasma and serum. A minimum of 36 replicates
of each dilution were tested over 3 days with three re-
agent lots on 3 Panther systems for a minimum of 108
replicates per dilution. In addition, the LLoQ across ge-
notypes was determined by testing dilutions of HCV
positive clinical specimens for genotypes 1, 2, 3, 4, 5 and
6 in HCV negative human plasma and serum. HCV
concentration of the clinical specimens was determined
using an FDA approved commercially available com-
parator assay. A minimum of 36 replicates of each dilu-
tion were tested over 3 days with each of three reagent
lots on 3 Panther systems for a minimum of 108
replicates per panel member. The LLoQ was calculated
using a total allowable error of 1 log.
Analytical specificity
Specificity of the Aptima assay was determined using 100
fresh and 270 frozen HCV negative plasma specimens and
98 fresh and 268 frozen HCV negative serum specimens.
Precision
To assess precision of the Aptima assay, nine positive
panel members made by diluting HCV genotype 1a virus
and armored RNA into HCV negative plasma were
tested in triplicate by one operator using one reagent lot
on one Panther systems over 21 test days.
Clinical specimen comparisons
Quantitative results for clinical specimens were obtained
by running specimens following the manufacturers’ in-
structions. Quantitative results were obtained for 1058
frozen clinical specimens with both the Aptima and
Abbott assays. These specimens represent all six HCV
Table 1 HCV Specimen Genotype & Origin
Country
of Origin
Total n GT 1 GT 2 GT 3 GT 4 GT 5 GT 6 Unknown
Algeria 13 10 2 1
Australia 33 1 4 22 1 5
Cambodia 3 3
Cameroon 25 8 5 12
Congo 2 2
Egypt 16 2 13 1
France 89 20 23 30 16




Gabon 9 1 8
Germany 11 6 1 4
Greece 406 145 19 179 63
Guadeloupe 2 1 1
Italy 85 50 24 3 8







Morocco 37 14 18 3 2
New Caledonia 1 1
Reunion Island 1 1
Russia 12 11 1
Senegal 1 1
Spain 34 20 3 8 3
Thailand 3 3
Tunisia 29 19 2 1 7
Unknown 28 17 11
USA 178 36 11 16 8 2 5 100
Vietnam 30 16 1 13
Total n 1058 358 126 270 147 19 37 101
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Fig. 1 Plasma Linearity for the Aptima Assay. Assay linearity for genotypes 1 to 6 was established by diluting armored RNA or HCV positive
clinical specimens in HCV negative plasma from 8.08 log IU/mL to below 1 log IU/mL. Armored RNA was used to make panels above 6 log IU/
mL. Clinical specimens were used to make lower concentrations with multiple levels of overlapping concentrations for armored RNA and clinical
specimen dilutions. The data for the armored RNA dilutions and the clinical specimen dilutions was combined for each genotype to generate the
data shown in the figure
Fig. 2 Serum Linearity for the Aptima Assay. Assay linearity for genotypes 1 to 6 was established by diluting armored RNA or HCV positive clinical
specimens in HCV negative serum from 8.08 log IU/mL to below 1 log IU/mL. Armored RNA was used to make panels above 6 log IU/mL. Clinical
specimens were used to make lower concentrations with multiple levels of overlapping concentrations for armored RNA and clinical specimen
dilutions. The data for the armored RNA dilutions and the clinical specimen dilutions was combined for each genotype to generate the data
shown in the figure
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genotypes and cover the full dynamic range of both as-
says. A subset of these specimens was also tested with
the Roche assay. From this subset, 611 gave quantitative
results with both the Abbott and Roche assays and 608
gave quantitative results with both the Aptima and
Roche assays. Three of the 611 specimens gave an in-
valid result with the Aptima assay, could not be retested
and were excluded from the analysis. Thus, the total
number of specimens used for the Aptima vs Roche
comparison was 608 and for the Abbott vs Roche com-
parison was 611. Comparable clinical performance of
quantitative measurements was demonstrated by linear
regression analysis and Bland Altman plots. The geno-
type distribution as reported by the vendor or lab
providing the specimens is shown in Table 1. One
hundred and one specimens did not have a genotype.
Agreement at low HCV Concentrations
One hundred and seven specimens that gave results at or
below 25 IU/mL using the Roche assays were compared.
For this analysis, results of “Target Not Detected” for
Roche or “Not Detected” for Aptima were interpreted as a
negative result. A valid result where HCV was detected or
quantified was interpreted as a positive result. Both posi-
tive and negative agreement between the Aptima assay
and the Roche assay was calculated. Where specimens did
not agree and sufficient specimen volume was available,
the specimen was tested using the Abbott assay.
The specimens using in the studies were obtained as
frozen deidentified remnant samples from the following
vendors or labs BioCollection, Miami, Florida, USA;
Boca Biolistics, Coconut Creek, Florida, USA;
Cerba Specimen Services, Saint-Ouen l’Aumone, France;
Discovery Life Sciences, Los Osos, California, USA;
Hellenic Scientific Society for the Study of AIDS and
Transmitted Diseases, Athens, Greece;
ProMedDx, Norton, Massachusetts, USA;
Table 2 Linear Equations for the Plots shown in Figs. 1 and 2
Matrix Genotype Linear Equation
Plasma 1 y = 1.05x - 0.04
2 y = 0.99x + 0.17
3 y = 1.02x - 0.02
4 y = 1.04x - 0.07
5 y = 1.01x - 0.04
6 y = 1.03x - 0.02
Serum 1 y = 1.05x + 0.00
2 y = 1.06x - 0.12
3 y = 1.02x + 0.05
4 y = 0.99x + 0.09
5 y = 1.00x + 0.04
6 y = 1.05x - 0.11





LLoQ LLoQ LLoQ LLoQ
(log IU/ml) (IU/ml) (log IU/ml) (IU/ml)
1 (WHO) 0.82 7 0.93 9
2 0.76 6 0.80 6
3 0.80 6 0.67 5
4 0.82 7 0.65 4
5 0.87 7 0.72 5
6 0.79 6 0.99 10
Table 3 LoD Probit Analysis Results in Plasma and Serum
HCV
Genotype
Plasma - Concentration In IU/mL (95% CI) Serum - Concentration In IU/mL (95% CI)
Lot 1 Lot 2 Lot 3 3 Lots Combined Lot 1 Lot 2 Lot 3 3 Lots Combined
1 (WHO) 3.3 2.5 4.3 3.4 2.8 3.3 3.9 3.4
(2.5–5.0) (1.9–3.9) (3.3–6.2) (2.9–4.3) (2.1 – 4.1) (2.5 – 5.1) (3.1 – 5.6) (2.9 – 4.2)
2 2.8 2.4 2.7 2.7 3.7 3.3 4.0 3.7
(2.2–3.9) (1.9–3.4) (2.3–3.5) (2.4–3.2) (3.0–5.3) (2.6–4.9) (3.1–5.8) (3.2–4.5)
3 3.3 4.3 3.1 3.8 2.7 2.9 3.4 3.0
(2.5–5.2) (3.2–6.5) (2.5–4.4) (3.2–4.8) (2.2–3.8) (2.4–4.1) (2.7–5.1) (2.6–3.6)
4 2.7 2.4 4.8 3.5 1.3 1.8 2.3 1.9
(2.2–3.7) (2.0–3.2) (3.9–6.3) (2.7–5.3) (1.0–2.4) (1.4–2.5) (1.7–3.5) (1.6–2.2)
5 2.0 1.6 2.1 2.0 2.8 2.2 3.2 2.8
(1.6–3.1) (1.3–2.4) (1.7–3.1) (1.6–2.6) (2.1–4.9) (1.8–3.5) (2.4–5.3) (2.4–3.6)
6 1.8 3.9 2.6 2.8 2.2 3.8 3.9 3.4
(1.4–2.9) (2.8–6.4) (2.0–3.9) (2.3–3.6) (1.7–3.2) (2.9–5.6) (3.0–5.7) (2.9–4.1)
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SeraCare Milford, Massachusetts, USA;
SlieaGen, Austin, Texas, USA;
Tissue Solutions Glasgow, Scotland;
ViroMed Minnetonka, Minnesota, USA
Statistical methods
The 95% positivity rates were estimated using Probit
analysis using the normal model and analysis software
from the SAS Institute, Cary, NC, USA.
The method comparison simple linear regression and
Bland Altman analysis were performed using Analyse-It
Software, Leeds, United Kingdom.
Linearity was measured using the R2 of the Pearson




As shown in Figs. 1 and 2, the Aptima assay displayed a
linear response from less than 1 log IU/mL to 8.08 log
IU/mL for genotypes 1, 2, 3, 4, 5 and 6 diluted in plasma
and serum. The equations of the linear plots for each
genotype are shown in Table 2. The R2 values for all the
linear fits were 1.00. The slopes ranged from 0.99 to
1.06 and the intercepts from −0.12 to 0.17.
Analytical sensitivity of Aptima
Table 3 shows the results of Probit analysis to determine
the LoD of HCV genotype 1–6 diluted into either serum
or plasma. Three reagent lots were used and the results
show the calculated LoD and 95% confidence intervals
for each lot separately as well as with all three lots com-
bined. For all genotypes, the calculated LoD was 5 IU/
mL or lower. The calculated LLoQ for each HCV geno-
type is shown in Table 4. The LLoQ varied by genotype
from 4 IU/ml for genotype 4 in serum to 10 IU/mL for
genotype 6 in serum.
Analytical specificity
The results from 370 HCV negative serum and 366
HCV negative plasma specimens are shown in Table 5.
Specimens included both fresh and previously frozen
specimens. All specimens gave a “Target Not Detected”
result for a specificity of 100% (95% confidence intervals
99.2 – 100% for both serum and plasma).
Precision
The CVs for inter-day, inter-run and intra-run and total
variation were all below 13.3% (Table 6). In all but one
case, the largest component of variation was intra-run
or random variation. The exception was for the serum
panel at 7.16 IU/mL where the intra-run variation was
0.55% but the inter-operator variation and inter-lot vari-
ation were 0.70 – 0.73% respectively.
Clinical specimen comparisons
Testing clinical specimens with the Aptima, Abbott and
Roche assays allowed a three-way comparison of assay
Table 5 Specificity for Plasma and Serum Specimens
Aptima HCV Quant Dx Fresh Plasma Frozen Plasma Plasma Total Fresh Serum Frozen Serum Serum Total
(n) 100 270 370 98 268 366
Target Not detected 100 270 370 98 268 366
Specificity (95% CI) 100% 100% 100% 100% 100% 100%
(97.1–100) (98.9–100) (99.2–100) (97.0–100) (98.9–100) (99.2–100)
Table 6 Precision of the Aptima Assay
Matrix Na Mean Concentration
(log IU/mL)
Inter-Operator Inter-Instrument Inter-Lot Inter-Run Intra-Run Total
SD CV (%) SD CV (%) SD CV (%) SD CV (%) SD CV (%) SD CV (%)
Plasma 98 1.23 0.00 0.00 0.00 0.00 0.04 3.35 0.06 4.54 0.12 9.84 0.14 11.34
Plasma 162 2.06 0.00 0.00 0.05 2.23 0.07 3.20 0.03 1.47 0.10 4.91 0.14 6.88
Plasma 162 3.02 0.01 0.24 0.03 0.89 0.04 1.47 0.01 0.33 0.09 3.08 0.11 3.77
Plasma 162 4.87 0.00 0.00 0.00 0.00 0.03 0.60 0.04 0.86 0.06 1.13 0.10 2.04
Plasma 162 7.16 0.01 0.20 0.02 0.21 0.04 0.52 0.00 0.00 0.05 0.75 0.09 1.27
Serum 132 1.27 0.00 0.00 0.00 0.00 0.07 5.16 0.00 0.00 0.15 12.17 0.17 13.31
Serum 162 2.17 0.04 1.71 0.02 0.99 0.07 3.01 0.05 2.15 0.08 3.53 0.12 5.61
Serum 162 3.09 0.00 0.00 0.02 0.67 0.06 1.79 0.03 0.90 0.07 2.26 0.11 3.44
Serum 161 4.86 0.04 0.78 0.00 0.00 0.08 1.67 0.00 0.00 0.08 1.72 0.13 2.65
Serum 162 7.16 0.05 0.70 0.00 0.00 0.05 0.73 0.02 0.31 0.04 0.55 0.10 1.35
aNumber of valid results within range of the assay
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performance to be made. Quantifiable results with both
the Aptima and Abbott assays were obtained for 1058
HCV clinical specimens. Linear regression analysis yielded
a slope of 1.06 (95% CI: 1.05 to 1.07), intercept of 0.08
(95% CI: 0.03 to 0.13), and R2 of 0.98 (Fig. 3, Additional
file 1). The slope and intercept were statistically significant
(p < 0.0001 and p = 0.002 respectively). By Bland-Altman
analysis (Fig. 4), the average bias was 0.34 log IU/mL with
95% acceptability limits of −0.20 to 0.88 log IU/mL. Quan-
tifiable results with both the Aptima and Roche assays
were obtained for 608 HCV positive clinical specimens.
Linear regression analysis yielded a slope of 1.05 (95% CI:
Fig. 3 Method Comparison: Aptima vs Abbott. The figure shows results quantifiable in both the Aptima and Abbott assays in log IU/mL for 1058
HCV positive clinical specimens. Linear regression analysis yielded a slope of 1.06 (95% CI: 1.05 to 1.07), intercept of 0.08 (95% CI: 0.03 to 0.13),
and R2 of 0.98
Fig. 4 Bland Altman Plot: Aptima vs Abbott. The figure shows results quantifiable in both the Aptima and Abbott assays in log IU/mL for 1058
HCV positive clinical specimens. Bland-Altman analysis was conducted comparing the difference between the Aptima and Abbott assays against
the average result for the two assays for each specimen. The average bias was 0.34 log IU/mL with 95% acceptability limits of −0.20 to 0.88
log IU/mL
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1.03 to1.07), intercept of 0.12 (95% CI: −0.20 to −0.04),
and R2 of 0.96 (Fig. 5, Additional file 1). The slope and
intercept were statistically significant (p < 0.0001 and p =
0.003 respectively). By Bland-Altman analysis (Figure 6),
the average bias was 0.11 log IU/mL with 95% acceptabil-
ity limits of −0.56 to 0.78 log IU/mL. Quantifiable results
with both the Roche and Abbott assays were obtained for
611 of the HCV positive clinical specimens. Linear regres-
sion analysis yielded a slope of 0.99 (95% CI: 0.98 to1.01),
intercept of −0.25 (95% CI: −0.32 to −0.19), and R2 of 0.97
(Fig. 7). The slope and intercept were statistically signifi-
cant (<0.0001). By Bland-Altman analysis (Fig. 8), the aver-
age bias was −0.27 log IU/mL with 95% acceptability
limits of −0.79 to −0.26 log IU/mL. A summary of the lin-
ear regression and bias calculations is shown in Table 7.
Agreement at low HCV Concentrations
Table 8 shows the agreement between Aptima and
Roche results using 107 specimens that gave an HCV
results </= 25 IU/mL using the Roche assay. Positive
Fig. 5 Method Comparison: Aptima vs Roche. The figure shows results quantifiable in both the Aptima and Roche assays in log IU/mL for 608 of
the HCV positive clinical specimens. Linear regression analysis yielded a linear regression slope of 1.05 (95% CI: 1.03 to1.07), intercept of 0.12 (95%
CI: −0.20 to −0.04), and R2 of 0.96
Fig. 6 Bland Altman Plot: Aptima vs Roche. The figure shows results quantifiable in both the Aptima and Roche assays in log IU/mL for 608
positive clinical specimens. Bland-Altman analysis was conducted comparing the difference between the Aptima and Roche assays against the
average result for the two assays for each specimen. The average bias was 0.11 log IU/mL with 95% acceptability limits of −0.56 to 0.78 log IU/mL
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agreement was 89% (47/53) and negative agreement was
also 89% (48/54). Six specimens gave a positive result in
the Aptima assay and a negative in the Roche assay
(Table 9). Sufficient volume was available to test four of
the six discordant specimens using the Abbott assay.
Two of the four gave detected but not quantifiable re-
sults in both Aptima and Abbott assays. The other two
gave quantifiable results above 25 IU/mL in both Aptima
and Abbott assays. There were six specimens that gave a
positive result by Roche but a negative result by Aptima
(Table 9). All the Roche results were detectable but not
quantifiable. Sufficient volume was available to test two
specimens with the Abbott assay and both gave negative
results.
Fig. 7 Method Comparison: Abbott vs Roche. The figure shows results quantifiable in both the Abbott and Roche assays in log IU/mL for 611
HCV positive clinical specimens. Linear regression analysis yielded a slope of 0.99 (95% CI: 0.98 to1.01), intercept of −0.25 (95% CI: −0.32 to −0.19),
and R2 of 0.97
Fig. 8 Bland Altman Plot: Abbott vs Roche. The figure shows results quantifiable in both the Abbott and Roche assays in log IU/mL for 611
positive clinical specimens. Bland-Altman analysis was conducted comparing the difference between the Aptima and Roche assays against the
average result for the two assays for each specimen. The average bias was −0.27 log IU/mL with 95% acceptability limits of −0.79 to −0.26
log IU/mL
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Discussion
As recommended by CDC, AASLD/IDSA and EASL
guidelines HCV NAAT can be used to confirm the pres-
ence of an active HCV infection or reinfection after pre-
vious viral clearance in patients with a positive HCV
antibody result [6, 8, 9]. Also, current testing guidelines
recommend viral load testing with a HCV NAAT prior
to initiating HCV therapy to determine the baseline viral
load level and to monitor patients while on therapy as
well as to detect a sustained virologic response. The data
presented in this paper supports the use of the Aptima
assay for these purposes.
To be effective as a diagnostic and viral load monitor-
ing test a NAAT assay must quantitate HCV results
across a wide dynamic range, be sensitive, specific, ac-
curate, precise and quantify all 6 HCV genotypes simi-
larly. Performance across a large dynamic range is
important because HCV RNA levels can reach over
10,000,000 IU/mL [12]. The linearity of the Aptima assay
across a wide dynamic range is shown in Figs. 1 and 2.
The correlation (R2) for samples diluted over a 7 log
range in HCV concentration was 1.00. The intercepts for
the linear plots were between −0.11 and 0.17 log IU/mL
indicating little bias and good linearity.
The sensitivity of the Aptima assay in both serum and
plasma is shown in Table 3. Probit analysis to determine
the LoD (95% positivity) of HCV genotypes 1–6 diluted
into either serum or plasma showed an LoD of 5 IU/mL
or lower in all genotypes. In addition, the LLoQ deter-
mined in serum and plasma for genotypes 1–6 was
10 IU/mL or lower. This level of sensitivity is important
because the end point for therapy of HCV is defined as
</=25 IU/mL so an assay must be able to accurately
quantitate at levels at or below 25 IU/mL [8]. It is rec-
ommended by EASL that for HCV diagnosis, an assay
with a lower limit of detection < 15 IU/mL is used [9]. It
has also been suggested that testing HCV levels below
50 IU/mL with highly sensitive assays can detect more
positive patients and that these patients are more likely
to relapse [13]. With a sensitivity of 10 IU/mL (LLoQ),
the Aptima assay is able to quantify HCV at the levels
needed for effective treatment monitoring and
diagnostics.
Specificity is also important to avoid false positive
results when diagnosing patients with HCV infections.
As shown in Table 5 the specificity of the Aptima HCV
was 100% for both serum and plasma specimens.
Sensitivity and specificity of the Aptima assay were
further tested using 107 specimens that gave an HCV
result </=25 IU/mL using the Roche assay. As shown in
Table 8, positive and negative agreement between the
Aptima and Roche assays was 89%. Four of the six sam-
ples negative by Roche and positive by Aptima, were also
tested in the Abbott assay. Two of these were detected
but not quantified by Abbott and Aptima. This indicates
that these two specimens likely contained very low levels
of HCV. However, the other two specimens tested by
the Abbott assay, gave results well above the limit of
quantitation (2.18 and 2.58 log IU/mL). These specimens
gave results of 1.97 and 2.64 log IU/mL respectively with
the Aptima assay. This confirms these two results as
false negative results by the Roche assay supporting the
superior sensitivity of the Aptima assay. There were six
results where the Roche assay detected HCV but the
Aptima did not. All six specimens gave detectable but








n 1058 608 611
R2 0.98 0.96 0.97
slope 1.06 1.05 1.00
95% CI for slope 1.04 to 1.07 1.03 to 1.07 0.98 to 1.01
Intercept 0.08 −0.12 −0.25
95% CI for intercept 0.03 to 0.13 −0.2 to −0.04 −0.32 to −0.19
average bias 0.34 0.11 −0.27
95% acceptability limits −0.20 to 0.88 −0.57 to 0.79 −0.79 to 0.25
Table 8 Agreement Between Aptima and Roche for Specimens
at or Below 25 IU/mL
Aptima
negative positive total
negative 48 6 54
Roche positive 6 47 53
% Agreement 89% 89%
Table 9 Discordant Specimens at or Below 25 IU/mL
Aptima Log IU/mL Abbott Log IU/mL Roche Log IU/mL
1.97 2.18 TND
2.64 2.59 TND
Detect <10 IU/mL Detected TND
Detect <10 IU/mL Detected TND
Detect <10 IU/mL NT TND








TND, Target Not Detected
ND, Not Detected
NT, Not tested
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not quantifiable results using the Roche assay. Of these
six specimens, two had sufficient volume to test using
the Abbott assay and both gave “not detectable” results.
Data from testing specimens with HCV levels at or
below 25 IU/mL suggests that the Aptima assay has bet-
ter sensitivity than the Roche assay and equivalent or
better specificity. The performance of the Aptima assay
compared to the reported performance of the Roche and
Abbott assays is summarized in Table 10. Based on this
data, it is expected that the Aptima assay should show
better sensitivity and comparable precision when meas-
uring low levels of HCV.
Good precision is an important requirement for an
assay used to monitor patients during treatment. A sin-
gle HCV RNA measurement may be used to confirm
that SVR has been reached. The data shown in Table 6
shows that the coefficient of variation for the assay is
below 13.3% even down to 1.2 log IU/mL (16 IU/mL).
This low variation gives a high degree of confidence that
a single RNA measurement using the Aptima assay will
provide a reliable result for determining SVR.
The method comparison between the Aptima and
Abbott assays used 1058 specimens obtained from over
30 different countries and included genotypes 1–6 repre-
senting a highly genetically diverse population of HCV.
Statistical analysis of this data set demonstrated a slope
of 1.06, an intercept of 0.08 and a correlation of 0.97.
The slope was statistically significant and was influenced
by slightly higher results for the Aptima assay above 5.5
log IU/mL. Although statistically significant, the magni-
tude of the difference is not clinically significant. The
method comparison between the Aptima and Roche
assays used 608 specimens. The slope of the Aptima
assay compared to the Roche assay was similar to that
seen when comparing the Aptima assay with the Abbott
assay (1.05 – 1.06). However, the average bias of the
Aptima assay by Bland Altman analysis was lower vs the
Roche assay (0.11 log IU/mL) compared to the Abbott
assay (0.34 log IU/mL). There were 611 specimens that
gave quantifiable results with both the Roche and Abbott
assays. A method comparison was conducted with these
data and gave a slope of 1.00, an intercept of −0.25 log
IU/mL and an average bias of −0.27 log IU/mL. All three
assays gave similar HCV viral load results indicating that
there is no need to re-baseline patients if switching to
the Aptima assay from the Roche and Abbott assays.
Conclusion
The Aptima assay has excellent sensitivity, specificity
and precision. It can measure HCV RNA levels over a
large dynamic range. The close agreement to the Abbott
and Roche assays suggests that a re-baseline of patients
is not required when switching to the Aptima assay for
HCV testing. The Aptima assay is an excellent candidate
for the diagnosis of HCV and monitoring HCV viral load
of patients on HCV therapy.
Additional file
Additional file 1: Method comparison Aptima Abbott Roche.
Supplemental data for VJ publication. (ZIP 16232 kb)
Abbreviations
AASLD: American Association for the study of Liver Disease; Abbott
RT: Abbott RealTime; Aptima Assay: Aptima HCV Quant Dx assay;
CDC: Centers for Disease Control; CV: Coefficient of variation; EASL: European
Association for the Study of the Liver; HCC: Hepatocellular carcinoma;
HCV: Hepatitis C Virus; IDSA: Infectious Disease Society of America; IVD:
In-vitro Diagnostic; LLOQ: Lower limit of Quantitation; LoD: Limit of
detection; mL: Millilitre; NAAT: Nucleic acid amplification tests;
RNA: Ribonucleic acid; TMA: Transcription Mediate Amplification; WHO: World
Health Organization
Acknowledgements
Brandon Henderson from Hologic Inc. helped run the Aptima assay for the
precision study.
Funding
Materials used in the studies were funded by Hologic Inc. DB, MH, TLN, CM,
CN, JKP, AW, MV, BV and AJW are employees of Hologic. AH and HP are
employees of National and Kapodistrian University of Athens.
Authors' contributions
AH contributed to writing the manuscript and helped procure the clinical
specimens used in the study. DB prepared samples, tested samples for the
precision study using the Aptima assay and analyzed data. JKP designed
multiple studies and analyzed data. HP prepared samples. TLN prepared and
tested samples for the specificity and precision studies and also analyzed
results. MH designed the precision study, prepared samples helped test
samples using the Aptima assay and analyzed data. CM prepared panels for
testing for multiple studies and analyzed results. CN generated samples for
testing the LoD and LLOQ studies and also analyzed the results. AW
procured and tested the specimens using the Aptima assay for the method
comparison. MV designed multiple studies and analyzed data. BV generate
samples for the linearity studies and analyzed the data. AJW contributed to
Table 10 Performance Summary of the Aptima, Roche and Abbott Assays
Assay 95% Limit of Detection
WHO standarda (IU/mL)






Aptima HCV Quant Dx plasma 4.3 serum 3.9 10 10-100,000,000 0.14 at 2.06 log IU/mL (115 IU/mL)
Abbott RealTime plasma 10.5 serum 7.2 12 10-100,000,000 0.10 at 1.96 log IU/mL (91 IU/mL)
Roche Ampliprep/ COBAS
Taqman HCV test v2.0
plasma 11 serum 12 15 10-100,000,000 </= 0.09 at 2.48 log IU/mL (300 IU/mL)
aSecond standard NIBSC 96/798 used for Aptima and Abbott. The third Standard NIBSC 06/100 for Roche Data taken from Aptima (11), Roche [14] and Abbott [15]
package inserts
Worlock et al. Virology Journal  (2017) 14:66 Page 11 of 12
writing the manuscript and analyzing the results. All authors read and




AH and EP declare that they have no competing interests DB, MH, TLN, CM,
CN, JKP, AW, MV, BV and AJW are employees of Hologic Inc.
Consent for publication
N/A.
Ethics approval and consent to participate
Patient informed consent is not required since the data were collected from
investigational testing, they were anonymized and cannot be linked to the
individuals. For the specimens obtained from Hellenic Scientific Society for
the Study of AIDS and Transmitted Disease, Athens, the study was approved
by the IRB of the Hellenic Scientific Society for the Study of AIDS and
Sexually Transmitted Diseases.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Hologic Inc., 10210 Genetic Center Drive, San Diego, CA 92121, USA.
2Department of Hygiene, Epidemiology and Medical Statistics, Medical
School, National and Kapodistrian University of Athens, Mikras Asias 75,
GR-11527 Athens, Greece. 3Hellenic Scientific Society for the Study of AIDS
and Sexually Transmitted Diseases, Athens, Greece.
Received: 27 September 2016 Accepted: 8 March 2017
References
1. World Health Organization (WHO). 2015. Hepatitis C. Fact sheet no. 164.
http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed 17 Mar
2017.
2. Chen SL, Morgan TR. The Natural History of Hepatitis C Virus (HCV)
Infection). Int J Med Sci. 2006;3(2):47–52.
3. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Decarli A, Trevisi P,
Ribero ML, Martelli C, Porru S, Nardi G. Alcohol and hepatocellular
carcinoma: The effect of lifetime intake and hepatitis virus infections in men
and women. Am J Epidemiol. 2002;155:323–3.
4. CDC, Division of Viral Hepatitis and National Center for HIV/AIDS, Viral
Hepatitis, STD, and TB Prevention. Hepatitis C FAQs for the public. Centers
for Disease Control and Prevention Web site. http://www.cdc.gov/hepatitis/
hcv/cfaq.htm. Accessed 17 Mar 2017.
5. Kardashian AA, Pockros PJ. New direct-acting antiviral therapies for
treatment of chronic hepatitis C virus infection. Gastroenterol Hepatol.
2015;11(7):458–66.
6. Recommendations for testing, managing, and treating hepatitis C. AASLD
and IDSA Web site. http://www.hcvguidelines.org/fullreport. Accessed 17
Mar 2017.
7. Van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F,
Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann P, De
Knegt RJ, Hansen BE, Janssen HLA. Association between sustained
virological response and all-cause mortality among patients with chronic
hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584–93.
8. CDC. Testing for HCV Infection: An Update of Guidance for Clinicians and
Laboratorians. MMWR 2013; 62(18);362–365. http://www.cdc.gov/mmwr/
preview/mmwrhtml/mm6218a5.htm. Accessed 17 Mar 2017.
9. EASL. Recommendations on Treatment of Hepatitis C. Hepatology.
2015;63:199–236.
10. Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a
systematic review. JAMA. 2014;312(6):631–40.
11. Aptima HCV Quant Dx package insert http://www.hologic.com/sites/default/
files/package%20inserts/AW-13249-001_001_01%20ENGLISH_0.pdf.
Accessed 17 Mar 2017.
12. O’Brien TR, Feld JJ, Kottilil S, Pfeiffer R. No scientific basis to restrict 8 weeks
of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus
RNA <6,000,000 IU/mL. Hepatology. 2015;63:28–30.
13. Dalgard O, Martinot-Peignoux M, Verbaan H, Bjøro K, Ring-Larsen H,
Marcellin P. The usefulness of defining rapid virological response by a very
sensitive assay (TMA) during treatment of HCV genotype 2/3 infection. PLoS
ONE. 2015;10(8):e0120866. doi:10.1371/journal.pone.0120866.
14. Roche PI 064503930001-01EN
15. Abbott PI Ref 1 N30-90 51-608374R1
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Worlock et al. Virology Journal  (2017) 14:66 Page 12 of 12
